Abstract 2929
Background
The human microbiome has been suggested to be involved in the regulation of response to anticancer strategies, however, information about how commensal microbes in a cancer patient change during radiotherapy is limited and the relationship between the microbiome and response to radiotherapy is poorly studied.
Methods
Sixty-two patients with nasopharyngeal carcinoma scheduled for radiotherapy-based treatment were prospectively enrolled. Nasopharyngeal swab samples were collected longitudinally during radiotherapy, and their microbial composition was assessed using 16S rRNA sequencing. All patients were followed up to 24 months after completion of radiotherapy.
Results
The beta-diversity of nasopharyngeal microbial communities (np-microbiome) showed changes throughout radiotherapy-based treatment. The magnitude of changes in the np-microbiome was stably and statistically significantly different between early and late responders (P = 0.02), with greater changes in early responders. This was confirmed in a temporal network analysis, where the networks varied widely in early responders, but were significantly more constrained in late responders (P = 0.009). Operational taxonomic units (OTUs) mapped to Corynebacterrium, Staphylococcus and Anaerococcus showed increasing loss with treatment, while all other abundant OTUs were stable over treatment. Twenty-seven abundant OTUs differed statistically, significantly (P < 0.05) by patients’ response throughout the treatment period.
Conclusions
The nasopharyngeal microbiome in NPC patients changes during radiotherapy-based treatment. These changes are statistically, significantly associated with patients’ response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Swedish Cancer Society; Swedish Research Council; National Natural Science Foundation of China; China Scholarship Council.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract